AIIMS Delhi is developing a low-cost antibody-based CAR-T cell therapy for multiple myeloma, a blood cancer. Targeting B-cell ...

Bioprocessing technology has a role to play in helping developers exert greater control over production processes.

For CRISPR Therapeutics specifically, that financial flexibility is not necessarily needed even if it's a plus. As of the most recent quarter, Q3, it reported having around $1.9 billion in cash, ...

As the founder and CEO of Immunocine Cancer Center, based in Cancún, Mexico, he has transformed his vision into reality with ...

"BrightPath and Cellistic partner for clinical trial advancements of CAR-T cell therapy" was originally created and published ...

Roswell Park Comprehensive Cancer Center next month will open a $98 million facility dedicated to developing new cancer ...

A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of ...

The new, long-term lease includes an immediate $12 million capital investment in facility upgrades, equipment and business ...

The most-read gene therapy articles included topics on FDA approvals, chimeric antigen receptor T-cell therapies, the ...

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science ...

Doctors at AIIMS, Delhi are in the process of developing a low-cost antibody-based adaptive cellular therapy for treatment of ...

According to latest data from National cancer registry, the estimated number of incident cases of cancer in India in 2022 was ...